AbbVie, Devon Energy And More On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, picked AbbVie Inc. (NYSE:ABBV).

The Chicago-based company’s stock price gained around 12% in the last month, and Snipe expects the momentum to continue.

On May 29, AbbVie announced the European Commission’s authorization of an expanded label for Venetoclax to include additional combinations for previously untreated chronic lymphocytic leukemia.

Don't forget to check out our premarket coverage here

Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, picked U.S. 10 Year Treasury.

SoFi ‘s Liz Young Thomas, meanwhile, recommended the U.S. 2 Year Treasury.

AbbVie, on May 29, announced European Commission authorization of expanded label for Venetoclax to include additional combinations in previously untreated chronic lymphocytic leukemia.

Joseph M. Terranova, senior managing director for Virtus Investment Partners, named Devon Energy Corp (NYSE:DVN) as his final trade.

Devon Energy shares surged on Wednesday after the company issued fresh guidance for 2026 following the completion of its merger with Coterra Energy. The combined business expects to produce about 1.38 million barrels of oil equivalent per day in 2026, with oil output projected at 500,000 barrels per day.

Evercore ISI Group analyst Stephen Richardson upgraded Devon Energy from In-Line to Outperform on Wednesday and set a $54 price target.

Price Action

• AbbVie shares fell 0.2% to close at $224.95 on Wednesday.
• Devon Energy shares jumped 5.8% to settle at $46.60 during the session.

Photo via Shutterstock